Search Results for: good news

Founding of The Allen Institute for Cell Science

Allen-Institute-for-Cell-Science

For the worlds of biology and cell biology including the stem cell field more specifically, the holidays came early with some fantastic news. Philanthropist and Microsoft co-Founder Paul Allen will give $100 million to form a new institute focused on cell biology in Seattle. The Allen Institute for Cell Science has an ambitious mission dedicated to

Founding of The Allen Institute for Cell Science Read More »

Harvard Predicts Fat Burning Stem Cell Pill To Replace Exercise

Moisan-et-al

A hot topic in biomedical sciences is converting white “bad” fat into brown “good” fat. The latter type of adipose is viewed more positively because it seems to be associated with a relatively metabolically more active, leaner state. Could we somehow convert white adipose to brown adipose and in so doing have a beneficial effect

Harvard Predicts Fat Burning Stem Cell Pill To Replace Exercise Read More »

Super Cells exhibit and why we bother with public outreach

Super-Cells

What are super cells? Guest post by Lisa Willemse Last month, on this blog, Paul wrote an article about loopholes in the clinicaltrials.gov database that allows for-profit companies to advertise their “therapies” under the guise of a registered clinical trial. This is a real concern for our community, especially those among us who have recommended

Super Cells exhibit and why we bother with public outreach Read More »

Open letter to UK Parliament: avoid historic mistake on rushing 3-parent technology

Dear UK Parliament and Science and Technology Committee, I am writing to you about your deliberations on “mitochondrial donation” (also known as 3-parent technology) intended for the purpose of preventing heritable mitochondrial disorders. I am concerned about the Department of Health’s recent draft regulations that would allow 3-parent experiments to go forward and the possibility that the UK

Open letter to UK Parliament: avoid historic mistake on rushing 3-parent technology Read More »

Interview with Jane Lebkowski on Asterias FDA-approved Stem Cell Trial

jane-lebkowski, Asterias

The BioTime subsidiary, Asterias, has received FDA approval for a combined Phase I/IIa clinical trial of OPC1 for treating spinal cord injury. BioTime (BTX) and Asterias (ASTY) have picked up the portfolio of the former Geron clinical trial using oligodendrocyte precursor cells (OPC). Asterias also acquired a second element from Geron in the form of a lung

Interview with Jane Lebkowski on Asterias FDA-approved Stem Cell Trial Read More »